<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Biotech Sector on FinanClub</title>
    <link>https://finan.club/tags/biotech-sector/</link>
    <description>Recent content in Biotech Sector on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Aug 2023 06:01:45 +0000</lastBuildDate><atom:link href="https://finan.club/tags/biotech-sector/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title> IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Tue, 08 Aug 2023 06:01:45 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:976
Chances: ImmunoGen, Inc. (IMGN) reports encouraging Q2 earnings with positive adoption of its sole-marketed drug Elahere, showing promising growth potential. The company&amp;rsquo;s strong Q2 financial results included significant positive surprises in both earnings and revenue, indicating a potential upward trend in the stock&amp;rsquo;s performance.</description>
    </item>
    
  </channel>
</rss>
